Findings of Research Misconduct, 12584-12585 [2018-05774]

Download as PDF daltland on DSKBBV9HB2PROD with NOTICES 12584 Federal Register / Vol. 83, No. 56 / Thursday, March 22, 2018 / Notices of the nomination package submitted for each individual being nominated: (1) A nomination letter clearly stating: a. Name and affiliation of the nominee; b. qualifications of the nominee related to the focus area(s) described above (i.e., specific attributes which qualify the nominee for service in this capacity); c. area (out of the three listed above) the nominee is interested in representing based on his/her experience and background; d. statement that the nominee is willing to serve as a member of the Committee; (2) The nominator’s name, address, and daytime telephone number; (3) The home and/or work address, telephone number, and email address of the individual being nominated; (4) A current copy of the nominee’s curriculum vitae or resume. The vitae or resume may be condensed to highlight the experience of the nominee related to the focus areas described above. An individual may self-nominate to be on the Committee. Federal employees should not be nominated for consideration of appointment to this Committee. Nominations that do not contain all of the above information will not be considered. Electronic submissions: Nomination materials, including attachments, may be submitted electronically to cfsac@ hhs.gov. An email from the CFSAC Support Team will be sent to the nominating individual or nominee to confirm receipt of the nomination. If the email confirmation is not received within two working days, please call 202–690–7650. Regular, Express, or Overnight Mail: Written documents may be submitted to the following addressee only: CDR Gustavo Ceinos, MPH, Designated Federal Officer, CFSAC, Office on Women’s Health, Office of the Assistant Secretary for Health, Department of Health and Human Services, 200 Independence Ave. SW, Room 728F6, Washington, DC 20201. Telephone and facsimile submissions cannot be accepted. The Department makes every effort to ensure that the membership of federal advisory committees is fairly balanced in terms of points of view represented. Appointment to this Committee shall be made without discrimination on the basis of age, race, ethnicity, gender, sexual orientation, disability, and cultural, religious, or socioeconomic status. Nominations must state that the nominee is willing to serve as a member of CFSAC and appears to have no conflict of interest that would preclude VerDate Sep<11>2014 19:32 Mar 21, 2018 Jkt 244001 membership. Candidates who are selected for appointment to the committee are required to provide detailed information concerning such matters as financial holdings, consultancies, and research grants or contracts for an ethics analysis to be conducted to identify potential conflicts of interest. Dated: March 14, 2018. Gustavo Ceinos, CDR, USPHS, Designated Federal Officer, Chronic Fatigue Syndrome Advisory Committee. [FR Doc. 2018–05833 Filed 3–21–18; 8:45 am] BILLING CODE 4150–42–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Findings of Research Misconduct Office of the Secretary, HHS. Notice. AGENCY: ACTION: Findings of research misconduct have been made on the part of Bhagavathi Narayanan, Ph.D., former Research Associate Professor, Department of Environmental Medicine, New York University (NYU). Dr. Narayanan engaged in research misconduct in research supported by National Cancer Institute (NCI), National Institutes of Health (NIH), grants R03 CA107813, R01 CA106296, R01 CA106296–05S1, R03 CA133929, and P30 CA017613. The administrative actions, including debarment for a period of three (3) years, were implemented beginning on February 26, 2018, and are detailed below. FOR FURTHER INFORMATION CONTACT: Wanda K. Jones, Dr. P.H., Interim Director, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453–8200. SUPPLEMENTARY INFORMATION: Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case: Bhagavathi Narayanan, Ph.D., New York University: Based on the report of an investigation conducted by NYU and analysis conducted by ORI in its oversight review, ORI found that Dr. Bhagavathi Narayanan, former Research Associate Professor, Department of Environmental Medicine, NYU, engaged in research misconduct in research supported by NCI, NIH, grants R03 CA107813, R01 CA106296, R01 CA106296–05S1, R03 CA133929, and P30 CA017613. ORI found that Respondent engaged in research misconduct by knowingly and intentionally falsifying and/or fabricating data reported in the SUMMARY: PO 00000 Frm 00025 Fmt 4703 Sfmt 4703 following three (3) published papers and seven (7) grant applications submitted to NIH: • Clin. Cancer Res. 9:3503–3513, 2003 (hereafter referred to as ‘‘Clin. Cancer Res. 2003’’) • Anticancer Res. 31(12):4347–4358, 2011 (hereafter referred to as ‘‘Anticancer Res. 2011’’) • Int. J. Oncol. 40:13–20, 2012 (hereafter referred to as ‘‘Int. J. Oncol. 2012’’) • R01 CA163381–01 • R01 CA138741–01A1 • R01 CA106296–06A1 • R01 CA106296–06A2 • R03 CA158253–01A1 • R21 CA170314–01 • R01 ES024139–01 ORI found that Respondent fabricated and/or falsified Western blot data for protein expression levels in cancer tissues and/or cells in fifty-eight (58) blot panels included in twenty-two (22) figures reported in three (3) papers and seven (7) grant applications submitted to NIH. In the absence of valid Western blot images, the quantitative data presented in associated bar graphs and statistical analyses also are false. Specifically, Respondent trimmed and/or copied Western blot images from unrelated sources, manipulated them to obscure their origin, and reused and relabeled them to represent different experimental results in: • Figures 5C, 6C, and 7C in Clin. Cancer Res. 2003 • Figures 2c, 4b, 6a, and 6b in Int. J. Oncol. 2012 • Figure 2B in Anticancer Res. 2011, also as Figure 1C in R01 CA163381– 01 • Figure 2A in Anticancer Res. 2011, also as Figure 1B in R01 CA163381– 01 • Figure 5D in Anticancer Res. 2011, also as Figure 8 in R01 CA163381–01 • Figure 1A in R01 CA163381–01 • Figure 6 in R01 CA138741–01A1 • Figure 4 in R01 CA106296–06A1 • Figure 4 in R01 CA106296–06A2 • Figures 3 and 6 in R03 CA158253– 01A1 • Figures 3 and 4 in R21 CA170314–01 • Figures 8A and 8B in R01 ES024139– 01 Dr. Narayanan entered into a Voluntary Exclusion Agreement and voluntarily agreed, beginning on February 26, 2018: (1) To exclude herself for a period of three (3) years from any contracting or subcontracting with any agency of the United States Government and from eligibility or involvement in nonprocurement programs of the United States Government referred to as ‘‘covered transactions’’ pursuant to E:\FR\FM\22MRN1.SGM 22MRN1 Federal Register / Vol. 83, No. 56 / Thursday, March 22, 2018 / Notices HHS’ Implementation (2 CFR part 376) of OMB Guidelines to Agencies on Governmentwide Debarment and Suspension, 2 CFR part 180 (collectively the ‘‘Debarment Regulations’’); (2) to exclude herself voluntarily from serving in any advisory capacity to the U.S. Public Health Service (PHS) including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee, or as a consultant for a period of three (3) years; and (3) as a condition of the Agreement, to the retraction of Anticancer Res. 31(12):4347–4358, 2011 (PMID: 22199300), and will request that this paper be retracted. Wanda K. Jones, Interim Director, Office of Research Integrity. [FR Doc. 2018–05774 Filed 3–21–18; 8:45 am] BILLING CODE 4150–31–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Environmental Health Sciences; Notice of Closed Meetings daltland on DSKBBV9HB2PROD with NOTICES Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Environmental Health Sciences Special Emphasis Panel; NIH Support of R13 Grant Applications. Date: April 5, 2018. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: NIEHS/National Institutes of Health, Building 4401, East Campus, 79 T.W. Alexander Drive, Research Triangle Park, NC 27709 (Telephone Conference Call). Contact Person: Janice B. Allen, Ph.D., Scientific Review Officer, Scientific Review Branch, Division of Extramural Research and Training, Nat. Institute of Environmental Health Science, P.O. Box 12233, MD EC–30/ Room 3170 B, Research Triangle Park, NC 27709, (919) 541–7556. Name of Committee: National Institute of Environmental Health Sciences Special VerDate Sep<11>2014 19:32 Mar 21, 2018 Jkt 244001 12585 Emphasis Panel; Maintain and Enrich Resource Infrastructure for Existing Environmental Epidemiology Cohorts. Date: April 11, 2018. Time: 10:30 a.m. to 3:30 p.m. Agenda: To review and evaluate grant applications. Place: NIEHS/National Institutes of Health, Keystone Building, 530 Davis Drive, Room 1002, Research Triangle Park, NC 27709 (Telephone Conference Call). Contact Person: Linda K. Bass, Scientific Review Officer, Scientific Review Branch, Division of Extramural Research and Training, Nat. Institute of Environmental Health Science, P.O. Box 12233, MD K3–03, Research Triangle Park, NC 27709, (919) 541– 1307. (Catalogue of Federal Domestic Assistance Program Nos. 93.115, Biometry and Risk Estimation—Health Risks from Environmental Exposures; 93.142, NIEHS Hazardous Waste Worker Health and Safety Training; 93.143, NIEHS Superfund Hazardous Substances—Basic Research and Education; 93.894, Resources and Manpower Development in the Environmental Health Sciences; 93.113, Biological Response to Environmental Health Hazards; 93.114, Applied Toxicological Research and Testing, National Institutes of Health, HHS) Place: National Institutes of Health, One Democracy Plaza, 6701Democracy Boulevard, Suite 703, Bethesda MD 20892. Contact Person: Mary A. Kelly, Scientific Review Specialist, National Institute of Nursing Research, National Institutes of Health, 6701 Democracy Boulevard, Suite 703, Bethesda, MD 20892, (301) 594–9695, mary.kelly@nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. (Catalogue of Federal Domestic Assistance Program Nos. 93.361, Nursing Research, National Institutes of Health, HHS) Dated: March 16, 2018. Natasha M. Copeland, Program Analyst, Office of Federal Advisory Committee Policy. [Docket ID: FEMA–2017–0014; OMB No. 1660–0016] [FR Doc. 2018–05849 Filed 3–21–18; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Nursing Research; Notice To Close Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Nursing Research Special Emphasis Panel; Loan Repayment Review. Date: March 26, 2018. Time: 1:00 p.m. to 2:00 p.m. Agenda: To review and evaluate grant applications. PO 00000 Frm 00026 Fmt 4703 Sfmt 4703 Dated: March 16, 2018. Sylvia L. Neal, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2018–05850 Filed 3–21–18; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HOMELAND SECURITY Federal Emergency Management Agency Agency Information Collection Activities: Submission for OMB Review; Comment Request; Revision to National Flood Insurance Program Maps: Application Forms and Instructions for LOMRs and CLOMRs Federal Emergency Management Agency, DHS. ACTION: Notice and request for comments. AGENCY: The Federal Emergency Management Agency (FEMA), as part of its continuing effort to reduce paperwork and respondent burden, invites the general public to take this opportunity to comment on a reinstatement, with change, of a previously approved information collection for which approval has expired. FEMA will submit the information collection abstracted below to the Office of Management and Budget for review and clearance in accordance with the requirements of the Paperwork Reduction Act of 1995. The submission will describe the nature of the information collection, the categories of respondents, the estimated burden (i.e., the time, effort and resources used by respondents to respond) and cost, and the actual data collection instruments FEMA will use. DATES: Comments must be submitted on or before April 23, 2018. ADDRESSES: Submit written comments on the proposed information collection SUMMARY: E:\FR\FM\22MRN1.SGM 22MRN1

Agencies

[Federal Register Volume 83, Number 56 (Thursday, March 22, 2018)]
[Notices]
[Pages 12584-12585]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-05774]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES


Findings of Research Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Findings of research misconduct have been made on the part of 
Bhagavathi Narayanan, Ph.D., former Research Associate Professor, 
Department of Environmental Medicine, New York University (NYU). Dr. 
Narayanan engaged in research misconduct in research supported by 
National Cancer Institute (NCI), National Institutes of Health (NIH), 
grants R03 CA107813, R01 CA106296, R01 CA106296-05S1, R03 CA133929, and 
P30 CA017613. The administrative actions, including debarment for a 
period of three (3) years, were implemented beginning on February 26, 
2018, and are detailed below.

FOR FURTHER INFORMATION CONTACT: Wanda K. Jones, Dr. P.H., Interim 
Director, Office of Research Integrity, 1101 Wootton Parkway, Suite 
750, Rockville, MD 20852, (240) 453-8200.

SUPPLEMENTARY INFORMATION: Notice is hereby given that the Office of 
Research Integrity (ORI) has taken final action in the following case:
    Bhagavathi Narayanan, Ph.D., New York University: Based on the 
report of an investigation conducted by NYU and analysis conducted by 
ORI in its oversight review, ORI found that Dr. Bhagavathi Narayanan, 
former Research Associate Professor, Department of Environmental 
Medicine, NYU, engaged in research misconduct in research supported by 
NCI, NIH, grants R03 CA107813, R01 CA106296, R01 CA106296-05S1, R03 
CA133929, and P30 CA017613.
    ORI found that Respondent engaged in research misconduct by 
knowingly and intentionally falsifying and/or fabricating data reported 
in the following three (3) published papers and seven (7) grant 
applications submitted to NIH:

 Clin. Cancer Res. 9:3503-3513, 2003 (hereafter referred to as 
``Clin. Cancer Res. 2003'')
 Anticancer Res. 31(12):4347-4358, 2011 (hereafter referred to 
as ``Anticancer Res. 2011'')
 Int. J. Oncol. 40:13-20, 2012 (hereafter referred to as ``Int. 
J. Oncol. 2012'')
 R01 CA163381-01
 R01 CA138741-01A1
 R01 CA106296-06A1
 R01 CA106296-06A2
 R03 CA158253-01A1
 R21 CA170314-01
 R01 ES024139-01

    ORI found that Respondent fabricated and/or falsified Western blot 
data for protein expression levels in cancer tissues and/or cells in 
fifty-eight (58) blot panels included in twenty-two (22) figures 
reported in three (3) papers and seven (7) grant applications submitted 
to NIH. In the absence of valid Western blot images, the quantitative 
data presented in associated bar graphs and statistical analyses also 
are false.
    Specifically, Respondent trimmed and/or copied Western blot images 
from unrelated sources, manipulated them to obscure their origin, and 
reused and relabeled them to represent different experimental results 
in:

 Figures 5C, 6C, and 7C in Clin. Cancer Res. 2003
 Figures 2c, 4b, 6a, and 6b in Int. J. Oncol. 2012
 Figure 2B in Anticancer Res. 2011, also as Figure 1C in R01 
CA163381-01
 Figure 2A in Anticancer Res. 2011, also as Figure 1B in R01 
CA163381-01
 Figure 5D in Anticancer Res. 2011, also as Figure 8 in R01 
CA163381-01
 Figure 1A in R01 CA163381-01
 Figure 6 in R01 CA138741-01A1
 Figure 4 in R01 CA106296-06A1
 Figure 4 in R01 CA106296-06A2
 Figures 3 and 6 in R03 CA158253-01A1
 Figures 3 and 4 in R21 CA170314-01
 Figures 8A and 8B in R01 ES024139-01

    Dr. Narayanan entered into a Voluntary Exclusion Agreement and 
voluntarily agreed, beginning on February 26, 2018:
    (1) To exclude herself for a period of three (3) years from any 
contracting or subcontracting with any agency of the United States 
Government and from eligibility or involvement in nonprocurement 
programs of the United States Government referred to as ``covered 
transactions'' pursuant to

[[Page 12585]]

HHS' Implementation (2 CFR part 376) of OMB Guidelines to Agencies on 
Governmentwide Debarment and Suspension, 2 CFR part 180 (collectively 
the ``Debarment Regulations'');
    (2) to exclude herself voluntarily from serving in any advisory 
capacity to the U.S. Public Health Service (PHS) including, but not 
limited to, service on any PHS advisory committee, board, and/or peer 
review committee, or as a consultant for a period of three (3) years; 
and
    (3) as a condition of the Agreement, to the retraction of 
Anticancer Res. 31(12):4347-4358, 2011 (PMID: 22199300), and will 
request that this paper be retracted.

Wanda K. Jones,
Interim Director, Office of Research Integrity.
[FR Doc. 2018-05774 Filed 3-21-18; 8:45 am]
 BILLING CODE 4150-31-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.